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Despite substantial advances in the treatment of acute lympho-
blastic leukemia (ALL) during the past four decades, long-term
survival remains at approximately 80% for children and 40% for
adults. The lack of efﬁcacy of treatment can be partly attributed
to the protection provided to the leukemia cells by the bone
marrow microenvironment. SDF-1a (CXCL12) is a cytokine
produced by bone marrow stromal cells that stimulates the
growth of pre-B cells. Its receptor, CXCR4, is expressed on
mature and precursor hematopoietic cells. The CXCL12–CXCR4
interaction was shown to be essential for the earliest stages
of B-cell development and is also involved in retaining
pre-B cells in the bone marrow. Original interest in CXCR4
from a therapeutic point of view was focused on its role as a
co-receptor for human immunodeﬁciency virus, but drugs that
block CXCR4, such as AMD3100, can also be used for
hematopoietic stem cell mobilization.
1 Juarez et al.
2,3 reported
that CXCR4 receptor-binding drugs inhibit CXCR4-mediated
functions of pre-B ALL cells in vitro and can mobilize trans-
planted ALL cells into the circulation of mice. However, the
effect of combined CXCR4 inhibition with chemotherapy on
ALL remains to be determined.
We previously showed that AMD3100 is able to block
protection provided by a stromal layer to mouse transgenic
Bcr/Abl P190 ALL cells treated with Imatinib.
4 To test whether
these results can be extended in vivo, we performed ﬂuores-
cence-activated cell sorting analysis on the peripheral blood of
leukemic P190 Bcr/Abl ALL (8093)-transplanted mice before
and 2h after intraperitoneal injection with saline or AMD3100,
as it has been shown that a single bolus of AMD3100 can
mobilize progenitor cells.
1 Interestingly, there was a marked
increase in circulating leukemic CD45.2
þ (8093 ALL) cells after
injection of AMD3100 (Figure 1a) but not in mobilized
CD45.1
þ C57BL/6 cells. This lack of effect on endogenous
CD45
þ cells may be caused by the suppression of normal
hematopoiesis by the presence of large numbers of malignant
lymphoblasts in the bone marrow at this stage. Using the same
model, we also examined whether AMD3100 is able to
repeatedly mobilize ALL cells in leukemic mice over a longer
period of time. As shown in Figure 1b, AMD3100 was able to
mobilize a similarly large number of cells into the circulation at
days 1 and 10, indicating a sustained mobilizing effect of this
drug. These results are consistent with those found in murine
transplant models of acute promyelocytic leukemia and multiple
myeloma .
5,6 To investigate whether their mobilization into the
peripheral blood will make ALL cells more vulnerable to drug
treatment, we next tested the combination effect of AMD3100
and nilotinib (AMN107) in vivo. Leukemia cells were allowed
to proliferate and generate a substantial tumor burden
before the start of treatment with phosphate-buffered saline,
nilotinib, AMD3100, or a combination of nilotinib and
AMD3100 (Figure 1c). As reported previously,
7 nilotinib
treatment prolonged the survival of mice. AMD3100 treatment
alone had no signiﬁcant beneﬁcial or detrimental effect on
survival (Figure 1c). Interestingly, combination therapy using
AMD3100 and nilotinib led to signiﬁcantly prolonged survival
in this murine leukemia model compared with treatment with
only nilotinib (Po0.05).
Figure 1 Combination therapy using AMD3100 and nilotinib
prolongs survival of murine ALL transplant recipients. C57Bl mice
transplanted with 10
4 Bcr/Abl P190 ALL 8093 cells were allowed to
develop full leukemia within 11–17 days. (a) Fold increase 2h after
injection in percentage CD45.1
þ or CD45.2
þ cells in peripheral
blood with respect to percentage before injection with phosphate-
buffered saline (PBS) or AMD3100 in the same animal (n¼3 per
group). (b) White blood cells on day 17 after transplant (treatment day
1), before and after injection with PBS or before and after injection
with 10mg/kg AMD3100 (n¼3 mice per group). Mice then received a
daily injection with PBS or AMD3100 for 9 more days. On treatment
day 10, white blood cells sampling, before and 2h after injection, was
repeated.
nPo0.05, paired Student’s t-test. (c) Leukemic transplanted
mice were treated with PBS, nilotinib/AMN107 (60mg/kg per d p.o.),
AMD3100 (10mg/kg per d i.p.) or nilotinibþAMD3100 (n¼6 per
group). NilotinibþAMD3100 versus nilotinib P¼0.047, log-rank test.
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www.nature.com/bcjWe veriﬁed that the AMD3100-mobilized cells included
ALL cells by engrafting non-obese diabetic/severe combined
immunodeﬁcient mice with the human pre-B ALL cell line 697.
As shown in Figure 2a, the increased white blood cells at 2h
after injection with AMD3100 (top) correlated with a signiﬁcant
increase in the peripheral blood of cells expressing human
CD19 (bottom), a marker that is highly expressed in this ALL
(499%, data not shown). We next tested the combined
treatment of chemotherapy and AMD3100 in vivo using primary
human US7R, a Philadelphia chromosome-negative ALL. At 12
days after transplant with US7R, mice were started on treatment
with phosphate-buffered saline, AMD3100, VDL (Vincristine,
Dexamethasone, L-asparaginase) or AMD3100 plus VDL. The
untreated control group died rapidly 27 days post-leukemia
injection (Figure 2b). Interestingly, mice treated with VDL plus
AMD3100 (MST¼61.5 days) survived signiﬁcantly longer
compared with those treated with VDL alone (MST¼54 days;
P¼0.015) or AMD3100 alone (MST¼27 days; P¼0.0022).
Treatment with AMD3100 appeared to be well tolerated, as
indicated by continuous weight gain in the treatment groups
(data not shown).
The concept of using mobilizing agents to bring ALL cells into
the circulation in which they can be more effectively treated
with other drugs had not been tested in vivo, although Juarez
et al.
2 did show that AMD3100 enhanced the cytotoxic and
anti-proliferative effects of vincristine and dexamethasone
in pre-B ALL cells in culture. In AML, AMD3465, a compound
related to AMD3100, enhanced the anti-leukemic effects of
chemotherapy and sorafenib in mouse transplant models.
8
Use of AMD3100 with Ara-C or with bortezomib in acute
promyelocytic leukemia or multiple myeloma also showed that
combination treatment sensitized these cancer cells to the
therapeutic drug in mouse models.
5,6 Moreover, there are
currently ongoing Phase clinical I/II trials (http://clinicaltrials.
gov identiﬁer: NCT00512252) for the study of AMD3100 in
relapsed or refractory acute myelogenous leukemia in combina-
tion with chemotherapy with mitoxantrone, etoposide and
cytarabine. In view of the fact, that our studies were performed
in models of very advanced primary ALL, in which the animals
were allowed to accumulate a substantial tumor burden before
treatment was initiated, combined with the fact that the human
US7R cells are largely unresponsive to the therapeutic drug
combination VDL (results not shown); the effect of AMD3100
combined with a second drug can be regarded as very
promising. Thus, clinical trials that test the usefulness of
combination treatment with CXCR4 antagonists for therapy of
relapsed or high-risk ALL appear to be warranted.
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Figure 2 Preclinical evaluation of AMD3100 as an adjuvant
treatment for human drug-resistant ALL. (a) Mobilization of human
ALL cells. At 12 days after transplant of human pre-B ALL 697 (6 10
6
cells/mouse) NOD/SCID/IL2Rg
 /  mice were injected i.p. with
phosphate-buffered saline (n¼3) or AMD3100 (30mg/kg) (n¼3).
White blood cells (top) or human CD19
þ cells in peripheral blood
(bottom) at 2h after injection.
nPo0.05, paired Student’s t-test.
(b) Survival of NOD/SCID/IL2Rg
 /  mice engrafted with primary ALL
(US7R) cells and treated with saline (circles, n¼2), VDL (vincristine
0.5mg/kg per d, dexamethasone 10.5mg/kg per d, L-asparaginase
1500IU/kg per day) (triangles up, n¼3), AMD3100 (10mg/kg per day)
(squares, n¼3) or VDL plus AMD3100 (triangle down, n¼6) for 28
days. AMD3100 was administered via a subcutaneous mini-osmotic
pump. VDLþAMD3100 versus VDL, P¼0.015, log-rank test.
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